NCT00395629

Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary Hemochromatosis

A Phase I/II Open Label, Dose Escalation Trial and a Six Month Extension to Explore the Safety and Efficacy of ICL670 in Patients With Iron Overload Resulting From Hereditary Hemochromatosis.

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 49 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Brief Summary: This study was designed to explore a safe dose and characterize the preliminary safety and efficacy of ICL670 in adult patients with previously documented history of homozygous C282Y.

Conditions

• Iron Overload
• Hereditary Hemochromatosis

Interventions

Type	Name	Description
DRUG	Deferasirox (ICL670)

Timeline

• Start date: 2006-08-01
• Primary completion: 2007-12-01
• Completion: 2009-03-01
• First posted: 2006-11-03
• Last updated: 2011-05-30
• Results posted: 2011-05-18

Locations

18 sites across 6 countries: United States, Australia, Canada, France, Germany, Italy